Health Policy

This cross-sectional study examines how civil monetary penalties compare to the profits of Medicare Advantage insurers to understand whether they are large enough to be a meaningful deterrent to violating program rules.

This cross-sectional study compares prices and facility characteristics of residential substance use facilities owned by private equity firms with other for-profit facilities and whether there are differences by ownership type.

This cohort study identifies variations in the care cascade for patients in need of coronary artery disease testing and cardiology referral after an emergency department visit.

Health Policy

This Viewpoint discusses how partnerships between public health and criminal justice organizations could help improve health and safety and minimize harms from gun violence.

This JAMA Forum discusses the declining costs and use of diagnostic imaging, the reasons for the imaging slowdown, and the future of imaging in the US health care system.

Health Policy

Health Policy

Health Policy

This cohort study examines prescription medication use and out-of-pocket spending among Indigenous and non-Indigenous Australians after a governmental program to reduce prescription drug co-payments.

This cohort study estimates long-term personal income losses following hospital diagnosis for selected mental and physical disorders, including depression, alcohol use disorder, stroke, and breast cancer.

This cohort study reports on the association of initiation of Medicaid home and community-based services with use of acute services.

This cohort study quantifies how many contracts became eligible for quality bonuses due to Categorical Adjustment Index (CAI) adjustments and estimates the association between CAI values, adjusted star ratings, and bonus status in Medicare Advantage contracts between 2014 and 2025.

This Viewpoint discusses the importance of patient and physician lawsuits and how the 2025 US Supreme Court decision Medina v Planned Parenthood South Atlantic may impede access to justice.

This JAMA Forum discusses the opportunities and challenges facing US Food and Drug Administration (FDA) new approval paths for individualized therapies to treat rare genetic diseases.

Health Policy

This case-control study assesses the association of losing insurance with diabetes outcomes among people with low income served by community health centers.

This economic evaluation examines the descriptive evidence contributing to the shortage of drugs used to treat attention-deficit/hyperactivity disorder in 2022 and 2023.

This cross-sectional study evaluates the effectiveness of expanding prenatal syphilis screening mandates on syphilis case detection during pregnancy.